Startups

Senior Manager, Lung Cross Portfolio, US Operations

Revolution Medicines · Redwood City, California, United States · On-site

← All jobs
About Revolution Medicines

Backed by GV.

About the role

The Senior Manager, Lung Cross Portfolio Operations role is essential to building operations capabilities across the US Lung Commercialization organization and contributing to achievement of cross functional, disease area and enterprise goals and objectives. The ideal candidate is a very proficient and proactive operations lead with strong ability to integrate planning across functions and enterprise stakeholders.

What they're looking for

  • Understand Commercialization launch strategies, stakeholders functional priorities and interdependencies and works cross functionally to develop and facilitate execution against plans
  • Act as primary portfolio operations contact for the cross functional launch forums and launch meetings
  • Manage the integrated launch plan and tracker - accounting for goals, objectives, deliverables, decisions, risks to align enterprise planning and tracking of launch progress
  • Manage an efficient information flow within the cross functional workstreams, and manage the preparation, review, editing and submission of project documents, presentations for internal advisory and governance meetings
  • Identify critical path activities, resource constraints, risks, and conflicts that could impact the timelines or budget, work with subject matter experts to construct appropriate mitigation plans
  • Contribute to scenario planning (comprising costs, timelines, risks, and project strategy) to inform stage gate, portfolio, budget and long-range planning
More about this role

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Senior Manager, Lung Cross Portfolio Operations role is essential to building operations capabilities across the US Lung Commercialization organization and contributing to achievement of cross functional, disease area and enterprise goals and objectives. The ideal candidate is a very proficient and proactive operations lead with strong ability to integrate planning across functions and...

Read the full posting on Revolution Medicines's site ↗

US Operations

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.